Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Stocks

Can Ladder Capital Weather the Storm Before Rates Fall?

Robert Sasse by Robert Sasse
August 28, 2025
in Stocks
0
Ladder Capital Stock
0
SHARES
296
VIEWS
Share on FacebookShare on Twitter

While markets rally on expectations of Federal Reserve rate cuts, the relief may arrive too late for specialized lenders like Ladder Capital. The company is already grappling with the severe financial pressures of an extended high-interest-rate environment. The critical question is whether the anticipated monetary policy pivot can provide a lifeline for the beleaguered real estate financier.

Robust Financials Amid Operational Headwinds

Despite significant operational challenges, Ladder Capital demonstrates considerable financial resilience. The firm maintains investment-grade credit ratings with stable outlooks from both Moody’s (Baa3) and Fitch (BBB-), a testament to its underlying solvency. Investor confidence was further illustrated by the successful issuance of a $500 million bond with a 5.5% coupon, which was oversubscribed by 5.5 times.

The company’s second-quarter 2025 results reveal several key strengths:
* Distributable earnings per share of $0.23, sufficiently covering its dividend payment
* A return on average equity of 7.7%
* Total liquidity of $1 billion, including $850 million in undrawn credit capacity
* Reduced commercial real estate loan exposure to 35%, down significantly from 65% in 2022

The Disconnect Between Fed Signals and Financial Reality

Recent comments from Fed Chair Jerome Powell suggesting potential rate cuts have generated optimism among interest-rate-sensitive securities, including Ladder Capital. However, the Q2 2025 financial results paint a stark picture of current challenges. Net interest income collapsed by 26%, while distributable earnings declined 24% to $30.9 million. The company continues to face substantial margin pressure from elevated refinancing costs in the current rate environment, with SOFR at 4.32% and the Prime Rate at 7.5%.

Should investors sell immediately? Or is it worth buying Ladder Capital?

Institutional Moves and Troubled Assets

Institutional investors have taken divergent positions on Ladder Capital’s prospects. Invesco reduced its stake by 6.9%, while Balyasny Asset Management and Bank of America increased their holdings. Notably, a company director sold shares worth approximately $1 million, while simultaneously, the firm itself executed $6 million in stock buybacks at an average price of $10.40 per share.

The company nevertheless faces substantial headwinds in its portfolio. Five loans totaling $162.3 million are currently non-performing, including a $150 million multifamily loan that has entered foreclosure. Second-quarter revenue of $56.26 million also fell short of market expectations.

While a shift in monetary policy could provide breathing room for Ladder Capital, whether it will be sufficient to address the fundamental issues plaguing the commercial real estate market remains uncertain.

Ad

Ladder Capital Stock: Buy or Sell?! New Ladder Capital Analysis from February 7 delivers the answer:

The latest Ladder Capital figures speak for themselves: Urgent action needed for Ladder Capital investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Ladder Capital: Buy or sell? Read more here...

Tags: Ladder Capital
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Eli Lilly Stock
Stocks

Eli Lilly’s Strategic Diversification Amid Weight-Loss Drug Competition

November 18, 2025
Micron Stock
Stocks

Micron Shares Approach Peak: What Comes After the AI Rally?

November 18, 2025
Varonis Stock
Stocks

Varonis Shares Plunge Amidst Mixed Signals

November 18, 2025
Next Post
Galectin Therapeutics Stock

Galectin Therapeutics Stock Surges Past Key Technical Benchmark

Great Lakes Dredge, Dock Stock

Strategic Fleet Expansion and Major Contracts Position Great Lakes Dredge & Dock for Growth

Torrid Holdings Stock

Torrid Holdings Faces Critical Earnings Test

Recommended

C3.ai Stock

Is C3.ai Stock Poised for a Rebound?

2 months ago
MMM stock news

Clarification on Hyperlink and Promotional Fees

2 years ago

XOMA Corporation Expands Portfolio with Acquisition of DSUVIA

2 years ago
Microsoft Stock

A Bold Bet: Peter Thiel’s Hedge Fund Doubles Down on Microsoft

1 month ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

ServiceNow Shares Face Market Skepticism Despite Record Performance

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

A New Chapter for First Busey as CrossFirst Merger Finalizes

Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

Myers Industries Set to Report Full-Year and Q4 2025 Results

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

Trending

Avanos Medical Stock
Analysis

Avanos Medical’s Strategic Pivot: A Focus on High-Margin Growth

by SiterGedge
February 7, 2026
0

Avanos Medical is navigating a critical strategic transformation. The medical device firm is streamlining its operations to...

Guaranty Bancshares Stock

Guaranty Bancshares Sees Growth Accelerate Following Texas Expansion

February 7, 2026
Yirendai Stock

Yirendai Charts a New Course with Tech-Driven Strategy

February 7, 2026
ServiceNow Stock

ServiceNow Shares Face Market Skepticism Despite Record Performance

February 7, 2026
Orthofix Medical Stock

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Avanos Medical’s Strategic Pivot: A Focus on High-Margin Growth
  • Guaranty Bancshares Sees Growth Accelerate Following Texas Expansion
  • Yirendai Charts a New Course with Tech-Driven Strategy

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com